Atrial fibrillation (AF) is the most common clinically relevant arrhythmia. AF is a strong independent risk factor for the subsequent development of heart failure (HF). HF and AF can interact to perpetuate and exacerbate each other. Soluble ST2 (sST2) is a biomarker of cardiomyocyte stretch that is useful in the diagnosis and prognosis of HF. Its role in the field of AF has not yet been well investigated. We studied the concentration of sST2 in a cohort of 174 subjects (62.1% men; mean age, 65.6 ± 10.3 years [± standard deviation (SD)]) with nonvalvular AF and 116 age-matched patients with sinus rhythm (SR). Subjects were subdivided into 3 groups: paroxysmal AF, persistent AF, and SR. Plasma sST2 concentrations were measured using an electrochemiluminescence-based immunoassay. The sST2 level was higher in persistent AF patients (P < 0.05) and paroxysmal AF patients (P < 0.05) than in SR patients. No significant difference was found between persistent AF and paroxysmal AF. sST2 was correlated with left atrial diameter (LAD) (r = 0.21; P < 0.01). During a median follow-up time of 6 months, 43 subjects with non-valvular AF in the study had HF. Cox proportional hazard analysis revealed both sST2 and LAD were independent predictors of HF. sST2 concentrations are higher in AF than SR. Plasma sST2 may be a useful biomarker in predicting HF in patients with AF.
A trial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. The incidence of AF is expected to increase significantly in the upcoming years due to the aging of the population, leading to increased healthcare costs. AF can cause major cardiovascular complications, including stroke and worsening heart failure (HF). 1) Despite being extensively studied, the mechanism of AF is still poorly understood. In recent years, growing evidence has supported the concept that inflammation, cardiac fibrosis, and remodeling may play important roles in AF.
2) Some circulating biomarkers are reflective of pathophysiological pathways, such as ventricular remodeling and fibrosis. IL-33/ST2L signaling plays a cardioprotective role in mechanical overload and antifibrotic effects.
ST2 is a member of the interleukin-1 receptor family and exists in 2 forms, as a transmembrane receptor (ST2L) as well as a soluble decoy receptor (sST2). A soluble form of ST2 is released from the myocardium and vascular endothelial cells in response to pressure or volume overload and relates to indices of hemodynamic load.
3) The increased knowledge about sST2 actions on the cardiovascular system led physicians to consider the assessment of plasma levels of sST2 as a novel marker of cardiovascular events and clinical conditions such as HF, myocardial infarction, and cardiac remodeling. [4] [5] [6] AF and HF often co-exist, and they can interact with each other. Because AF and other cardiovascular diseases, such as HF and coronary heart disease share many risk factors and underlying pathophysiologic mechanisms, we hypothesized that sST2 linked to these cardiovascular disorders could be of value in AF. No single study has explored the usefulness of sST2 in AF. The aim of the present study was to investigate whether serum levels of sST2 differ in patients with different patterns of AF compared with patients with sinus rhythm (SR). We, therefore explored whether sST2 could predict HF in AF.
Methods

Study population:
This was a hospital-based singlecenter prospective cohort study of inpatients with a diag-ST2 AND ATRIAL FIBRILLATION nosis of nonvalvular AF. From 2014 to 2015, a total 174 subjects (62.1% men; mean age, 65.6 ± 10.3 years [± standard deviation (SD)]) with AF and 116 age-matched patients with sinus rhythm (SR) were consecutively enrolled in the study. The criterion and classification of AF used were based on the 2014 American Heart Association (AHA) guidelines. 7) Paroxysmal AF was defined as AF that terminates spontaneously or with intervention within 7 days of onset. Persistent AF was defined as continuous AF that was sustained > 7 days. Exclusion criteria were as follows: acute myocardial infarction, stroke, congenital heart disease, significant HF (New York Heart Association (NYHA) functional classification !3), chronic pulmonary heart disease, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy, inflammatory states, autoimmune disease, and thyroid dysfunction. Clinical information included standard demographics, medical history and drug therapy, presenting symptoms and signs (including severity of breathlessness by NYHA), physical examination, results of serum chemistry tests, radiographic studies (typically plain chest radiographs), electrocardiography, and ultrasonic cardiogram (UCG) results. Blood samples were obtained routinely from fasting participants and processed immediately. The medium follow-up period was 6 months (range, 5-7 months). Each HF episode was diagnosed according to the European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. 8) This study complies with the Ethics Review Board of the First Affiliated Hospital of Wenzhou Medical University, and all participants provided written informed consent. Plasma sST2 assay: Venous blood samples were obtained at enrollment, processed, and stored at -80 until analyzed (not later than 3 months). sST2 was measured by a sandwich-double monoclonal antibody enzyme-linked immunosorbent assay (ELISA) method, according to the manufacturer's protocol (Boyun, Shanghai, China). Briefly, plasma samples and standards were incubated in microwells coated with an anti-human ST2 antibody. After washing, a peroxidase-conjugated anti-human ST2 antibody was added into the microwell and incubated. After a second washing, the peroxidase substrate was added, and the optical density at 450 nm was determined. A laboratory scientist blinded to the clinical information performed the ST2 assay. Transthoracic echocardiography: Studies were performed by an experienced echocardiographer according to the recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. 9) We used the M mode to measure the anteroposterior diameter of the left atrium (LAD) as in the parasternal long-axis view perpendicular to the aortic root long axis. Echocardiography measurements included left ventricular ejection fraction (LVEF), LAD, left ventricular end-diastolic diameter (LVEDd), inter-ventricular septal thickness at end diastole (IVSd), and the posterior wall thickness at end diastole (PWTd). Statistical analysis: SPSS software version 16 (SPSS, Chicago, IL, USA) was used for the statistical analyses.
Continuous variables were tested for normal distribution using the Kolmogorov-Smirnov test. Summary descriptive statistics for continuous parameters are presented as the mean ± standard deviation (SD). Variables not normally distributed are reported as the median with interquartile ranges (IQRs). The frequencies of categorical variables are expressed as numbers (percentage). Categorical variables were compared among study groups using the χ 2 test or the Fisher exact test. The Wilcoxon or Kruskal-Wallis test was used for nonsymmetric continuous parameters among 2 or 3 groups. Student's t-test (for comparison of continuous parameters between 2 groups) or 1-way ANOVA (for comparison of continuous parameters among 3 groups) was used. Correlations analysis was used to determine the relationship between variables. Receiver-operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off points for sST2 for predicting HF. Predictors of HF occurrence were examined by univariate and multivariate Cox proportional hazard analysis. In order to fulfill the assumption of linearity of the co-variables of sST2, cut-offs of sST2 were used in the Cox proportional hazard analysis. P values of < 0.05 from two-sided tests were considered to indicate statistical significance.
Results
Comparisons of clinical characteristics:
The baseline clinical and laboratory characteristics of the study population are displayed in Table I . Patients with persistent AF had the largest LAD (48.1 ± 6.4 mm), while patients with SR had the smallest LAD (40.6 ± 5.6 mm). Compared with paroxysmal AF patients, persistent AF patients had higher DBP and heart rate. There were no differences with regard to gender, age, body mass index (BMI), LVEF, fasting blood sugar, kidney function, liver function, and fasting lipid profile between the 3 study groups. The other clinical features, including the presence of coronary artery disease, hypertension, diabetic mellitus (DM), gout, smoking, alcoholism, and the use of cardiovascular medications, did not differ significantly between the 3 groups. sST2 and brain natriuretic peptide (BNP) according to type of AF: As presented in Table I , sST2 was elevated in persistent AF (285.0 (236.7, 389.6) ng/L, P > 0.05), and paroxysmal (276.4 (191.4, 398.5) ng/L, P < 0.05) versus control (222.4 (152.0, 302.5) ng/L), while no significant difference was found between persistent AF and paroxysmal AF. Patients with AF had higher serum levels of sST2 and BNP than the SR group. Plasma levels of BNP were numerically higher in patients with persistent AF than in patients with paroxysmal AF, while sST2 showed no difference between the 2 groups. Subjects with persistent AF had the highest levels of BNP among the 3 groups, while subjects with SR had the lowest levels of BNP. Relationship between sST2 and UCG (LAD): The echocardiographic characteristics of the entire study cohort are shown in Table I . Patients with persistent AF had greater LAD. Serum sST2 concentrations had a close relationship with LAD (r = 0.21; P < 0.01).
Utility of sST2 levels to predict HF recurrence in AF:
A total of 174 patients were followed up with a monthly physician visit. Twelve patients with AF were lost to Chen, ET AL Data are mean ± SD, median (25th to 75th percentiles) or number (%). *P < 0.05 overall; **P < 0.05 comparing patients with paroxysmal AF and SR, ΔP < 0.05 comparing patients with persistent AF and SR, P < 0.05 comparing paroxysmal and persistent AF. BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ALT, glutamic pyruvic transaminase; AST, glutamic oxaloacetic transaminase; Cr, creatinine; Ccr, creatinine clearance rate; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; TC, total cholesterol; FBG, fasting blood glucose; TSH, thyroid stimulating hormone; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVST, left ventricular septum thickness; LVPWT, left ventricular posterior wall thickness; DM, diabetic mellitus; ACEI, angiotensin converting enzyme inhibitors; and MI, myocardial infarction.
follow-up, so the withdrawal rate was 6.90%. HF occurred in 43 patients (26.5%). Figure 1 shows the ROC curves of sST2 for predicting HF in AF patients. Data were pooled to determine the diagnostic utility of sST2 for the detection of HF in AF. The ROC curve for the sST2 area under the curve was 0.60 (95% CI, 0.51 to 0.69; P = 0.02). Using the sST2 value of !219.3 ng/L, sST2 had a sensitivity of 95.4% and a specificity of 34.5%. To determine the potential utility of sST2 assessment, we divided the subjects into two groups based upon the sST2 cut-off points, as shown in Table II . Survival analysis showed that patients with sST2 !219.3 ng/L was significantly lower in free of HF rate than those with sST2 < 219.3 ng/L (45.3% versus 94.3% χ 2 = 8.26, P < 0.01), as shown in Figure 2 .
Univariate and multivariate Cox proportional hazard analyses revealed recurrent HF was associated with increased LAD (hazard ratio = 1.06; 95%CI, 1.02-1.10; P < 0.01) and sST2 levels (hazard ratio = 5.88; 95%CI, 1.42-24.45; P = 0.02) (Table III) .
Discussion
Several studies have established the prognostic role of sST2 levels in myocardial infarction and HF. 4, 5, 10) The results of the present study indicated that AF is connected with higher sST2 levels to a greater extent than SR. Serum sST2 was positively correlated with LAD. Serum sST2 could serve as an independent biomarker for predicting HF in AF patients.
Pathophysiologically increased hemodynamic load causes atrial stretch, which is a well-known cause of AF development, which may also stimulate sST2 and BNP secretion. sST2 levels increased during AF, possibly because patients with AF have a higher heart rate and atrial pressure than patients in SR. ST2/IL-33 signaling is thought ST2 AND ATRIAL FIBRILLATION to play an important role in regulating the myocardial response to biomechanical overload in stretched cardiac fibroblasts and cardiomyocytes. Loss of IL-33/ST2L signaling results in ventricular myocardium remodeling by excessive myocyte hypertrophy, fibrosis, and worsening of left ventricular (LV) function, along with a higher risk of death from ventricular failure.
11)
Previous studies have shown that BNP levels were elevated and were significantly higher in persistent AF than in paroxysmal AF. 12) BNP levels in patients with paroxysmal AF were significantly higher than SR, 13) and the present findings are in agreement with this. Although BNP is useful in HF, it has limitations. For example, factors, such as age or renal function may affect the results. Therefore, sST2 may complement and supplant the role of BNP in AF. Knock-out of the ST2 gene leads to a phenotype, not unlike that seen in BNP knock-out models, with severe myocyte hypertrophy and interstitial cardiac fibrosis.
11) The ST2 gene is highly expressed when cardiomyocytes and fibroblasts are strained. 14) sST2 levels were linked to larger LV dimensions and volumes.
Another important finding was that sST2 correlated well with LAD. Due to atrial histological remodeling, such as fibrosis, AF patients had greater LAD. Atrial dilatation is the major marker of left atrium remodeling. Atrial remodeling promotes the occurrence or maintenance of AF. 15) sST2 levels are predicted by a phenotype of cardiac decompensation and remodeling.
Multivariate analyses showed that LAD was an independent risk factor for recurrence of HF in AF patients. Many conditions are associated with LA remodeling and dilation. LA enlargement is often the result of pressure and/or overload. These LA chamber changes in cardiac hemodynamics are common in AF patients due to the high prevalence of comorbidities, such as hypertension, HF and CAD. It was reported that AF patients with LA enlargement had a greater incidence of HF. 16) In a catheterization and echocardiography study, HF patients with AF were associated with larger LA dilatation, which is similar to the current data. 17) In a large prospective study, patients with incident chronic heart failure (CHF) during follow-up had higher LAD.
18) The mechanism is thought to drive the increasing atrial loading, resulting in remodeling, apoptosis, myosin isoform expression, collagen matrix turnover, and reduced intrinsic contractility.
AF is associated with a 3-fold risk of HF. It was simple and easy to use biomarkers to evaluate HF. As an emerging cardiovascular biomarker for the presence of ventricular biomechanical overload, sST2 has been found to have diagnostic and prognostic value in patients with destabilized HF as well as chronic severe HF. sST2 has elicited interest as a potential aid to predict the prognosis of and manage the treatment of HF. Recent clinical practice guidelines support the use of the sST2 assay for risk stratification in HF outpatients. 19) However, a recent study revealed that in a healthy general population from Finland, sST2 did not improve the long-term prediction of cardiovascular events, including HF. 20) The diagnostic utility of sST2 in AF has not been studied as extensively. The principle finding of the current study is that serum sST2 may be able to predict HF in AF. sST2 that reflects the degree of myocardial stress and fibrosis may enhance risk stratification. AF is a strong independent risk factor for the subsequent development of HF. HF and AF can interact to perpetuate and exacerbate each other. Among 98,811 patients with incident new AF, 22.0% had HF. 21) Over one-third of patients with AF also experienced HF events. 22) The presence of both AF and HF portended a higher mortality risk than either condition alone. 23) It is important to have a simple method for identifying which patients are at high risk of HF recurrence. Measurement of sST2 levels may be a simple and useful method for Chen, ET AL predicting the HF of patients with AF. As is known, serum sST2 levels are elevated and associated with outcomes in patients with HF.
24)
Study limitations: This study has several limitations. First, we excluded NYHA !III because NYHA !III may affect the sST2. Therefore, whether the study conclusion can be applied to the whole AF population remains unanswered. Second, the number of subjects enrolled in the study was limited due to the single center design. Third, a highly sensitive assay for the sST2 measurement was not used. Fourth, the follow-up period was short. Fifth, a single measurement of sST2 was taken, but not a serial testing. Sixth, the potential impacts of the cardiovascular medications on hemodynamics or biomarkers could not be completely excluded. In addition, the use of cardiovascular medication was similar (Table I) between the 3 groups.
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This could make the impact of these medications on biomarkers less significant.
Conclusion
Plasma sST2 levels are higher in AF than SR. Serum sST2 could serve as an independent biomarker for predicting HF in AF patients. However, our study group is too small to permit any definite conclusions. A prospective study with long-term follow-up would shed more light on this subject.
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